Advertisement

Containing Global Antibiotic Resistance: Ethical Drug Promotion in the Developing World

  • Catherine Olivier
  • Bryn Williams-Jones
  • Béatrice Doizé
  • Vural Ozdemir
Chapter

Abstract

The introduction of antimicrobial agents was a breakthrough health intervention that helped save millions of lives around the world and that provided a sense of control on the part of clinicians over host–pathogen interactions. Yet despite the concrete advances in prevention and treatment of infectious diseases, there has been a parallel surge in resistance to antimicrobials that is seriously compromising the gains made over the past century. Acknowledging the underlying mechanisms such as inappropriate use of antibiotics in humans and the agricultural applications of antibiotics for growth promotion and prophylaxis is a first and essential step to contain global antimicrobial resistance. However, it is also critical to consider in parallel the broad social, economic and political drivers and ethical significance of antimicrobial promotion in developing countries. Moreover, these socio-ethical factors constitute tangible targets against which public policy interventions can be developed to remedy growing concerns over the spread of antimicrobial resistance. In this chapter, we focus on drug promotion practices in the developing world that have important repercussions on physician prescribing habits, antimicrobial use and development of resistance. Other social factors that are endemic in developing countries – such as inadequate resources in health and education systems – can amplify erratic or suboptimal drug use. The public health consequences of, and ethical responsibilities associated with, drug promotion are substantially larger when viewed through the prism of the realities faced by persons living in developing countries. In our world of increasing urbanization and globalization, the actions of pharmaceutical companies have a global impact. Thus, their social responsibilities extend beyond developing medications for the populations of the developing world, to include socio-ethical and public health consideration for populations worldwide. Focusing on the fact that ‘what happens in the developing world does not stay in the developing world’, we propose that ethical considerations should be included as an integral part of the framework in the evaluation of appropriateness of drug promotion practices.

Keywords

Pharmaceutical Company Antimicrobial Resistance Antimicrobial Drug Promotional Material Ethical Criterion 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgments

Supported in part by an ethics operating seed grant from the Canadian Institutes of Health Research and a career scientist award in ethics, science and society research from the Fonds de la recherche en santé du Québec to Vural Ozdemir. We thank Anne-Marie Dion for constructive critique and expert advice on pharmaceutical advertising and promotion. Catherine Olivier was supported by a fellowship from the Centre de Recherche en Éthique at the University of Montreal, and from the Canadian Institutes of Health Research. The ideas expressed represent the personal views of the authors only.

References

  1. Aarestrup, F. M. 2005. Veterinary drug usage and antimicrobial resistance in bacteria of animal origin. Basic Clin Pharmacol Toxicol 96: 271–281.CrossRefPubMedGoogle Scholar
  2. Anthony, F., Acar, J., Franklin, A., Gupta, R., Nicholls, T., Tamura, Y., et al. 2001. Antimicrobial resistance: responsible and prudent use of antimicrobial agents in veterinary medicine. Rev Sci Tech 20: 829–839.PubMedGoogle Scholar
  3. Bancroft, E. A. 2007. Antimicrobial resistance: it's not just for hospitals. JAMA 298: 1803–1804.CrossRefPubMedGoogle Scholar
  4. Barza, M. and Gorbach, S. 2002. The need to improve microbial use in agriculture: ecology and human health consequences. Clin Infect Dis 34: S71–S144.CrossRefPubMedGoogle Scholar
  5. BBC News. 2005. Brazil may break Aids drug patent. Brazil has threatened to break the patent on an anti-Aids drug in order to make a cheaper generic version. http://news.bbc.co.uk/go/pr/fr/-/2/hi/americas/4621735.stm.
  6. BBC News. 2007. Uganda opens first HIV drug plant. A factory that will produce treatments for HIV/Aids is opening in Uganda, the first of its kind in the country http://news.bbc.co.uk/2/hi/africa/7033162.stm.
  7. Benkimoun, P. 2005. Le paludisme, un tueur du tiers-monde. Le Monde. Paris.Google Scholar
  8. Bhutta, T. I. 1996. Deception by design: pharmaceutical promotion in the Third World. Br Med J 313:60.Google Scholar
  9. Brodie, M. and Levitt, L. 2002. Drug advertising: the right or wrong prescription for our ailments? Nat Rev Drug Discov 1: 916–920.CrossRefPubMedGoogle Scholar
  10. Byarugaba, D. K. 2004. A view on antimicrobial resistance in developing countries and responsible risk factors. Int J Antimicrob Agents 24: 105–110.CrossRefPubMedGoogle Scholar
  11. Corpet, D. E. 1988. Antibiotic resistance from food. N Engl J Med 318: 1206–1207.PubMedGoogle Scholar
  12. Dal-Pizzol, F. 2002. Drug advertisements in less-developed countries. Lancet 359: 1439–1440.CrossRefPubMedGoogle Scholar
  13. Deshpande, A., Menon, A., Perri, M., 3rd and Zinkhan, G. 2004. Direct-to-consumer advertising and its utility in health care decision making: a consumer perspective. J Health Commun 9: 499–513.CrossRefPubMedGoogle Scholar
  14. Dipeolu, M. and Alonge, D. 2002. Residues of streptomycin antibiotic in meat sold for human consumption in some states in Nigeria. Arch Zootec 51: 477–480.Google Scholar
  15. Donald, A. 1999. Technology transfer: the problem with “trickle down” theory. Br Med J 319: 1298–1299.Google Scholar
  16. Dugger, C. W. 2007. U.N. predicts urban population explosion. The New York Times. New York.Google Scholar
  17. Dukes, G. M. N. 2002. Accountability of the pharmaceutical industry. Lancet 360: 1682–1684.CrossRefPubMedGoogle Scholar
  18. Fidler, D. P. 1998. Legal issues associated with antimicrobial drug resistance. Emerg Infect Dis 4: 169–177.CrossRefPubMedGoogle Scholar
  19. Findlay, S. D. 2001. Direct-to-consumer promotion of prescription drugs. Economic implications for patients, payers and providers. Pharmacoeconomics 19: 109–119.CrossRefPubMedGoogle Scholar
  20. Garcia-Rey, C., Aguilar, L., Baquero, F., Casal, J. and Martin, J. E. 2002. Pharmacoepidemiological analysis of provincial differences between consumption of macrolides and rates of erythromycin resistance among Streptococcus pyogenes isolates in Spain. J Clin Microbiol 40: 2959–2963.CrossRefPubMedGoogle Scholar
  21. Gassman, N. 1999. Social and economic value: two sides of the self-medication coin. Responsible self-medication: a challenge to consumers and industry. The World Self-Medication Industry (WSMI) 13th General Assembly, The Association of the European Self-Medication Industry (AESGP) 35th Annual Meeting, Self-care – a vital element of health policy in the information age. Berlin.Google Scholar
  22. Gaur, A. H. and English, B. K. 2006. The judicious use of antibiotics – an investment towards optimized health care. Indian J Pediatr 73: 343–350.CrossRefPubMedGoogle Scholar
  23. Harris, G. 2007. Minnesota limit on gifts to doctors may catch on. The New York Times. New York.Google Scholar
  24. Hart, C. A. and Kariuki, S. 1998. Antimicrobial resistance in developing countries. Br Med J 317: 647–650.Google Scholar
  25. Heath, J. 2006. Business ethics without stakeholders. Bus Ethics Q 16: 533–557.Google Scholar
  26. Hodges, B. 1995. Interactions with the pharmaceutical industry: experiences and attitudes of psychiatry residents, interns and clerks. CMAJ 153: 553–559.PubMedGoogle Scholar
  27. Hoek, J. and Gendall, P. 2002. Direct-to-consumer advertising down under: an alternative perspective and regulatory framework. J Public Policy Mark 21: 202–212.CrossRefGoogle Scholar
  28. Hogerzeil, H. V. 2004. The concept of essential medicines: lessons for rich countries. 329: 1169–1172.Google Scholar
  29. Islam, M. S. and Farah, S. S. 2007. Misleading promotion of drugs in Bangladesh: evidence from drug promotional brochures distributed to general practitioners by the pharmaceutical companies. J Public Health (Oxf) 29: 212–213.CrossRefGoogle Scholar
  30. Jaderberg, M. 2002. The pharmaceutical industry – a key partner in providing information to the patient and a key player in the European debate on direct to consumer communication. Int J Med Mark 2: 179–183.CrossRefGoogle Scholar
  31. Katz, D., Caplan, A. L. and Merz, J. F. 2003. All gifts large and small. Am J Bioeth 3: 39–46.CrossRefPubMedGoogle Scholar
  32. Klevens, R. M., Morrison, M. A., Nadle, J., Petit, S., Gershman, K., Ray, S., et al. 2007. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 298: 1763–1771.CrossRefPubMedGoogle Scholar
  33. Kolawole, D. and Shittu, A. 1997. Unusual recovery of animal staphylococci from septic wounds of hospital patients in Ile-Ife, Nigeria. Lett Appl Microbiol 24: 87–90.CrossRefPubMedGoogle Scholar
  34. Kumarasamy, N., Safren, S. A., Raminani, S. R., Pickard, R., James, R., Krishnan, A. K., et al. 2005. Barriers and facilitators to antiretroviral medication adherence among patients with HIV in Chennai, India: a qualitative study. AIDS Patient Care STDS 19: 526–537.CrossRefPubMedGoogle Scholar
  35. Kunin, C. M. 1993. Resistance to antimicrobial drugs – a worldwide calamity. Ann Intern Med 118: 557–561.PubMedGoogle Scholar
  36. Lal, A. 1998. Information contents of drug advertisements: an Indian experience. Ann Pharmacother 32: 1234–1238.CrossRefPubMedGoogle Scholar
  37. Lexchin, J. 1987. Advertisement scrutiny. Lancet 1: 1323–1324.CrossRefPubMedGoogle Scholar
  38. Lu, H. Z., Weng, X. H., Li, H., Yin, Y. K., Pang, M. Y. and Tang, Y. W. 2002. Enterococcus faecium-related outbreak with molecular evidence of transmission from pigs to humans. J Clin Microbiol 40: 913–917.CrossRefPubMedGoogle Scholar
  39. Master, Z. and Ozdemir, V. 2008. Selling translational research: is science a value-neutral autonomous enterprise? Am J Bioeth 8(3): 52–54CrossRefPubMedGoogle Scholar
  40. Mastin, T., Andsager, J. L., Choi, J. and Lee, K. 2007. Health disparities and direct-to-consumer prescription drug advertising: a content analysis of targeted magazine genres, 1992–2002. Health Commun 22: 49–58.PubMedGoogle Scholar
  41. McCaig, L. F., Besser, R. E. and Hughes, J. M. 2002. Trends in antimicrobial prescribing rates for children and adolescents. JAMA 287: 3096–3102.CrossRefPubMedGoogle Scholar
  42. McCaig, L. F., Besser, R. E. and Hughes, J. M. 2003. Antimicrobial drug prescription in ambulatory care settings, United States, 1992–2000. Emerg Infect Dis 9: 432–437.PubMedGoogle Scholar
  43. McCaig, L. F., Hooker, R. S., Sekscenski, E. S. and Woodwell, D. A. 1998. Physician assistants and nurse practitioners in hospital outpatient departments, 1993–1994. Public Health Rep 113: 75–82.PubMedGoogle Scholar
  44. Menkes, D. B. 1997. Hazardous drugs in developing countries. Br Med J 315: 1557–1558.Google Scholar
  45. Menkes, D. B. 2006. Calling the piper's tune. Primary Care Commun Psychiatry 11: 147–149.CrossRefGoogle Scholar
  46. Mintzes, B. 1998. Blurring the boundaries: new trends in drug promotion. In: Promotion Targeting Consumers. Amsterdam: HAI-Europe www.haiweb.org/pubs/blurring/blurring.intro.html Dated Accessed January 20, 2009.
  47. Mintzes, B. 2006. Disease mongering in drug promotion: do governments have a regulatory role? PLoS Med 3: e198.CrossRefPubMedGoogle Scholar
  48. Mitema, E. S., Kikuvi, G. M., Wegener, H. C. and Stohr, K. 2001. An assessment of antimicrobial consumption in food producing animals in Kenya. J Vet Pharmacol Ther 24: 385–390.CrossRefPubMedGoogle Scholar
  49. MSNBC. 2006. WHO calls for halt on malaria treatment. Agency fears improper use may lead to drug resistance. Associated Press.Google Scholar
  50. Muriuki, F. K., Ogara, W. O., Njeruh, F. M. and Mitema, E. S. 2001. Tetracycline residue levels in cattle meat from Nairobi slaughter house in Kenya. J Vet Sci 2: 97–101.PubMedGoogle Scholar
  51. Mutume, G. 2001. Health and intellectual property; poor nations and drug firms tussle over WTO patent provisions. Africa Recover 15(1): 14–15.Google Scholar
  52. Na Iampang, K., Chongsuvivatwong, V. and Kitikoon, V. 2007. Pattern and determinant of antibiotics used on broiler farms in Songkhla province, southern Thailand. Trop Anim Health Prod 39: 355–361.CrossRefGoogle Scholar
  53. Nicholls, T., Acar, J., Anthony, F., Franklin, A., Gupta, R., Tamura, Y., et al. 2001. Antimicrobial resistance: monitoring the quantities of antimicrobials used in animal husbandry. Rev Sci Tech. 20: 841–847.PubMedGoogle Scholar
  54. Norris, P., Herxheimer, A., Lexchin, J. and Mansfield, P. 2005. Drug promotion. What we know, what we have yet to learn. Reviews of materials in the WHO/HAI database on drug promotion. Amsterdam: WHO/HAI.Google Scholar
  55. Okeke, I. N., Klugman, K. P., Bhutta, Z. A., Duse, A. G., Jenkins, P., O'Brien, T. F., et al. 2005. Antimicrobial resistance in developing countries. Part II: strategies for containment. Lancet Infect Dis 5: 568–580.CrossRefPubMedGoogle Scholar
  56. Okeke, I. N., Lamikanra, A. and Edelman, R. 1999. Socioeconomic and behavioral factors leading to acquired bacterial resistance to antibiotics in developing countries. Emerg Infect Dis 5: 18–27.CrossRefPubMedGoogle Scholar
  57. Oyugi, J. H., Byakika-Tusiime, J., Charlebois, E. D., Kityo, C., Mugerwa, R., Mugyenyi, P., et al. 2004. Multiple validated measures of adherence indicate high levels of adherence to generic HIV antiretroviral therapy in a resource-limited setting. J Acquir Immune Defic Syndr 36: 1100–1102.CrossRefPubMedGoogle Scholar
  58. Ozdemir, V., Aklillu, E., Mee, S., Bertilsson, L., Albers, L., Graham, J. E., et al. 2006. Pharmacogenetics for off-patent antipsychotics: reframing the risk for tardive dyskinesia and access to essential medicines. Expert Opin Pharmacother 7: 119–133.CrossRefPubMedGoogle Scholar
  59. Ozdemir, V. and Godard, B. 2007. Evidence-based management of nutrigenomics expectations and ELSIs. Pharmacogenomics 8:1051–1062.CrossRefPubMedGoogle Scholar
  60. Ozdemir, V., Graham, J. E. and Godard, B. 2008. Race as a variable in pharmacogenomics research: From empirical ethics to publication standards. Pharmacogenet Genomics 18(10): 837–841.Google Scholar
  61. Petersen, A., Andersen, J., Kaewmak, T., Somsiri, T. and Dalsgaard, A. 2002. Impact of integrated fish farming on antimicrobial resistance in a pond environment. Appl Environ Microbiol 68: 6036–6042.CrossRefPubMedGoogle Scholar
  62. Phillips, I., Casewell, M., Cox, T., De Groot, B., Friis, C., Jones, R., et al. 2004. Does the use of antibiotics in food animals pose a risk to human health? A critical review of published data. J Antimicrob Chemother 53: 28–52.CrossRefPubMedGoogle Scholar
  63. Projan, S. J. 2003. Why is big Pharma getting out of antibacterial drug discovery? Curr Opin Microbiol 6: 427–430.CrossRefPubMedGoogle Scholar
  64. Quick, J. D. 2003. Ensuring access to essential medicines in the developing countries: a framework for action. Clin Pharmacol Ther. 73: 279–283.CrossRefPubMedGoogle Scholar
  65. Richet, H. M., Mohammed, J., McDonald, L. C. and Jarvis, W. R. 2001. Building communication networks: international network for the study and prevention of emerging antimicrobial resistance. Emerg Infect Dis 7: 319–322.CrossRefPubMedGoogle Scholar
  66. Rogers, W. A., Mansfield, P. R., Braunack-Mayer, A. J. and Jureidini, J. N. 2004. The ethics of pharmaceutical industry relationships with medical students. Med J Aust 180: 411–414.PubMedGoogle Scholar
  67. Rolland, R. M., Hausfater, G., Marshall, B. and Levy, S. B. 1985. Antibiotic-resistant bacteria in wild primates: increased prevalence in baboons feeding on human refuse. Appl Environ Microbiol 49: 791–794.PubMedGoogle Scholar
  68. Rollin, B. 2001. Ethics, science and antimicrobial resistance. J. Agric Environ Ethics 14: 29–37.CrossRefGoogle Scholar
  69. Semin, S., Aras, S. and Guldal, D. 2007. Direct-to-consumer advertising of pharmaceuticals: developed countries experiences and Turkey. Health Expect 10: 4–15.CrossRefPubMedGoogle Scholar
  70. Simango, C. and Rukure, G. 1991. Potential sources of campylobacter species in the homes of farmworkers in Zimbabwe. J Trop Med Hyg 94: 388–392.PubMedGoogle Scholar
  71. Spear, B. B., Heath-Chiozzi, M. and Huff, J. 2001. Clinical application of pharmacogenetics. Trends Mol Med 7: 201–204.CrossRefPubMedGoogle Scholar
  72. Spellberg, B., Powers, J. H., Brass, E. P., Miller, L. G. and Edwards, J. E., Jr. 2004. Trends in antimicrobial drug development: implications for the future. Clin Infect Dis 38: 1279–1286.CrossRefPubMedGoogle Scholar
  73. Talbot, G. H., Bradley, J., Edwards, J. E., Jr., Gilbert, D., Scheld, M. and Bartlett, J. G. 2006. Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin Infect Dis 42: 657–668.CrossRefPubMedGoogle Scholar
  74. Tuffs, A. 2004. Only 6% of drug advertising material is supported by evidence. Br Med J 328: 485.CrossRefGoogle Scholar
  75. Usluer, G., Ozgunes, I. and Leblebicioglu, H. 2005. A multicenter point-prevalence study: antimicrobial prescription frequencies in hospitalized patients in Turkey. Ann Clin Microbiol Antimicrob 4: 16.CrossRefPubMedGoogle Scholar
  76. Vancelik, S., Beyhun, N. E., Acemoglu, H. and Calikoglu, O. 2007. Impact of pharmaceutical promotion on prescribing decisions of general practitioners in Eastern Turkey. BMC Public Health 7: 122.CrossRefPubMedGoogle Scholar
  77. Vidaver, A. K. 2002. Uses of antimicrobials in plant agriculture. Clin Infect Dis 34 Suppl 3: S107–S110.CrossRefGoogle Scholar
  78. Waud, D. 1992. Pharmaceutical promotions – a free lunch? N Engl J Med. 327: 351–353.CrossRefPubMedGoogle Scholar
  79. Wazana, A. 2000. Physicians and the pharmaceutical industry: is a gift ever just a gift? JAMA 283: 373–380.CrossRefPubMedGoogle Scholar
  80. World Consumer Rights Day (WCRD). 2007. Unethical Drug Promotion.Google Scholar
  81. Wenzel, R. P. 2004. The antibiotic pipeline – challenges, costs, and values. N Engl J Med 351: 523–526.CrossRefPubMedGoogle Scholar
  82. World Health Organization. (WHO) http://www.who.int/medicines/en.
  83. World Health Organization. (WHO). 1988. Criteria for medicinal drug promotion. Geneva: World Health Organization.Google Scholar
  84. World Health Organization. (WHO). 1998. Emerging and other communicable diseases: antimicrobial resistance. Geneva: World Health Organization.Google Scholar
  85. World Health Organization. (WHO). 2001. Pharmaceutical promotion. IN WHO global strategy for containment of antimicrobial resistance. Executive Summary, World Health Organization (Ed.). 51–53. Geneva: World Health Organization.Google Scholar
  86. WHO. 2006. Facts on acts (artemisinin-based combination therapies). Geneva: World Health Organization.Google Scholar
  87. WHO. 2007. Resistance to artemisinin derivatives along the Thai-Cambodian border. Weekly Epidemiol Rec 82(41): 360.Google Scholar
  88. Yamey, G. 2001. US trade action threatens Brazilian AIDS programme. Br Med J 322: 383.CrossRefGoogle Scholar
  89. Yoshikawa, T. T. 2002. Antimicrobial resistance and aging: beginning of the end of the antibiotic era? J Am Geriatr Soc 50: S226–S229.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Catherine Olivier
    • 1
  • Bryn Williams-Jones
    • 1
  • Béatrice Doizé
    • 2
    • 3
  • Vural Ozdemir
    • 4
  1. 1.Programmes de bioéthique, Département de médicine sociale et préventive, Faculté de médicineUniversité de MontréalMontréalCanada
  2. 2.Département de pathologie et microbiologie, Faculté de médecine vétérinaireUniversité de MontréalMontréalCanada
  3. 3.Faculté de médecine vétérinaire – Université de MontréalMontréalCanada
  4. 4.Bioethics Programs, Department of Social and Preventive Medicine, Faculty of MedicineUniversity of MontréalMontréalCanada

Personalised recommendations